Inflammasomes and intestinal inflammation

Mucosal Immunology

Volumn 10, Issue 4, 2017, Pages 865-883

  Zmora, N ^a,b   Levy, M ^a   Pevsner Fishcer, M ^a   Elinav, E ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AIM2 PROTEIN; CRYOPYRIN; DEXTRAN SULFATE; INFLAMMASOME; NEURONAL APOPTOSIS INHIBITORY PROTEIN; NLRC4 PROTEIN; NLRP1 PROTEIN; NLRP12 PROTEIN; NLRP6 PROTEIN; OXAZOLONE; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOIMMUNE DISEASE; CARCINOGENESIS; CITROBACTER RODENTIUM; CLINICAL FEATURE; COLITIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; ECOSYSTEM; ENTERITIS; ENTEROBACTERIACEAE INFECTION; HOMEOSTASIS; HUMAN; INTESTINAL HOMEOSTASIS; INTESTINE FLORA; MICROBIOME; NONHUMAN; PATHOPHYSIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PHAGOSOME; PRIORITY JOURNAL; PROTEUS MIRABILIS; REVIEW; SIGNAL TRANSDUCTION; TISSUE INJURY; YERSINIA PSEUDOTUBERCULOSIS; ANIMAL; GASTROENTERITIS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; INNATE IMMUNITY; INTESTINE; METABOLISM; MICROBIOLOGY; PROCEDURES;

ANIMALS; GASTROENTERITIS; GASTROINTESTINAL MICROBIOME; HOMEOSTASIS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMASOMES; INFLAMMATION; INTESTINES;

EID: 85020846957     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2017.19     Document Type: Review

References (228)

1. Thaiss, C. A., Zmora, N., Levy, M. & Elinav, E. The microbiome and innate immunity. Nature 535, 65-74 (2016).
2. Medzhitov, R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135-145 (2001).
3. Akira, S. & Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499-511 (2004).
4. Duncan, J. A. et al. Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc. Natl Acad. Sci. USA 104, 8041-8046 (2007).
5. Lamkanfi, M. & Dixit, V. M. Inflammasomes and their roles in health and disease. Annu. Rev. Cell Dev. Biol. 28, 137-161 (2012).
6. Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10, 417-426 (2002).
7. Lamkanfi, M. & Dixit, V. M. Mechanisms and functions of inflammasomes. Cell 157, 1013-1022 (2014).
8. Lupfer, C. & Kanneganti, T.-D. The expanding role of NLRs in antiviral immunity. Immunol. Rev. 255, 13-24 (2013).
9. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805-820 (2010).
10. Schroder, K. et al. The inflammasomes. Cell 140, 821-832 (2010).
11. Zaki, M. H., Lamkanfi, M. & Kanneganti, T.-D. The Nlrp3 inflammasome: contributions to intestinal homeostasis. Trends Immunol. 32, 171-179 (2011).
12. Mitoma, H. et al. The DHX33 RNA helicase senses cytosolic RNA and activates the NLRP3 inflammasome. Immunity 39, 123-135 (2013).
13. Shimada, K. et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36, 401-414 (2012).
14. Murakami, T. et al. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc. Natl Acad. Sci. USA 109, 11282-11287 (2012).
15. Compan, V. et al. Cell volume regulation modulates NLRP3 inflammasome activation. Immunity 37, 487-500 (2012).
16. Zambetti, L. P., Laudisi, F., Licandro, G., Ricciardi-Castagnoli, P. & Mortellaro, A. The rhapsody of NLRPs: master players of inflammation. and a lot more. Immunol. Res. 53, 78-90 (2012).
17. Muñoz-Planillo, R. et al. K efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38, 1142-1153 (2013).
18. He, Y., Zeng, M. Y., Yang, D., Motro, B. & Núñez, G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 530, 354-357 (2016).
19. Song, H. et al. The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3. Nat. Commun. 7, 13727 (2016).
20. Roy, N., Deveraux, Q. L., Takahashi, R., Salvesen, G. S. & Reed, J. C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16, 6914-6925 (1997).
21. Rodgers, M. A. et al. The linear ubiquitin assembly complex (LUBAC) is essential for NLRP3 inflammasome activation. J. Exp. Med. 211, 1333-1347 (2014).
22. Lopez-Castejon, G. et al. Deubiquitinases regulate the activity of caspase-1 and interleukin-1b secretion via assembly of the inflammasome. J. Biol. Chem. 288, 2721-2733 (2013).
23. Py, B. F., Kim, M.-S., Vakifahmetoglu-Norberg, H. & Yuan, J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol. Cell 49, 331-338 (2013).
24. Hirota, S. A. et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm. Bowel Dis. 17, 1359-1372 (2011).
25. Zaki, M. H. et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 32, 379-391 (2010).
26. Allen, I. C. et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 207, 1045-1056 (2010).
27. Itani, S. et al. NLRP3 inflammasome has a protective effect against oxazolone-induced colitis: a possible role in ulcerative colitis. Sci. Rep. 6, 39075 (2016).
28. Bauer, C. et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59, 1192-1199 (2010).
29. Bauer, C., Duewell, P., Lehr, H.-A., Endres, S. & Schnurr, M. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors. Dig. Dis. 30 (Suppl 1), 82-90 (2012).
30. Siegmund, B., Lehr, H. A., Fantuzzi, G. & Dinarello, C. A. IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc. Natl Acad. Sci. USA 98, 13249-13254 (2001).
31. Ishikura, T. et al. Interleukin-18 overproduction exacerbates the development of colitis with markedly infiltrated macrophages in interleukin-18 transgenic mice. J. Gastroenterol. Hepatol. 18, 960-969 (2003).
32. Becker, H. M., Apladas, A., Scharl, M., Fried, M. & Rogler, G. Probiotic Escherichia coli Nissle 1917 and commensal E. coli K12 differentially affect the inflammasome in intestinal epithelial cells. Digestion 89, 110-118 (2014).
33. Loher, F. et al. The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1T-cell activation. J. Pharmacol. Exp. Ther. 308, 583-590 (2004).
34. Bauer, C. et al. The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6 mice and suppresses IP-10 mRNA but not TNF-a mRNA expression. Dig. Dis. Sci. 52, 1642-1652 (2007).
35. Siegmund, B. et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-g and TNF-a production. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281, R1264-R1273 (2001).
36. Sivakumar, P. V. et al. Interleukin 18 is a primarymediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 50, 812-820 (2002).
37. Liu, L. et al. The pathogenic role of NLRP3 inflammasome activation in inflammatory bowel diseases of bothmice and humans. J. Crohn's Colitis, jjw219 (2016) (doi:10. 1093/ecco-jcc/jjw219).
38. Filardy, A. A., He, J., Bennink, J., Yewdell, J. & Kelsall, B. L. Posttranscriptional control of NLRP3 inflammasome activation in colonic macrophages. Mucosal Immunol. 9, 850-858 (2016).
39. Higashimori, A. et al. Mechanisms of NLRP3 inflammasome activation and its role in NSAID-induced enteropathy. Mucosal Immunol 9, 659-668 (2016).
40. Sokolovska, A. et al. Activation of caspase-1 by the NLRP3 inflammasome regulates the NADPH oxidase NOX2 to control phagosome function. Nat. Immunol. 14, 543-553 (2013).
41. Seo, S.-U. et al. Distinct commensals induce interleukin-1b via NLRP3 inflammasome in inflammatory monocytes to promote intestinal inflammation in response to injury. Immunity 42, 744-755 (2015).
42. Ng, J. et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology 139, 542-552. 552-3 (2010).
43. Thinwa, J., Segovia, J. A., Bose, S. & Dube, P. H. Integrin-mediated first signal for inflammasome activation in intestinal epithelial cells. J. Immunol. 193, 1373-1382 (2014).
44. Brodsky, I. E. et al. A Yersinia effector protein promotes virulence by preventing inflammasome recognition of the type III secretion system. Cell Host Microbe 7, 376-387 (2010).
45. Borenshtein, D., McBee, M. E. & Schauer, D. B. Utility of the Citrobacter rodentium infection model in laboratory mice. Curr. Opin. Gastroenterol. 24, 32-37 (2008).
46. Eckmann, L. Animal models of inflammatory bowel disease: lessons from enteric infections. Ann. N. Y. Acad. Sci. 1072, 28-38 (2006).
47. Mundy, R., MacDonald, T. T., Dougan, G., Frankel, G. & Wiles, S. Citrobacter rodentium of mice and man. Cell. Microbiol. 7, 1697-1706 (2005).
48. Song-Zhao, G. X. et al. Nlrp3 activation in the intestinal epithelium protects against a mucosal pathogen. Mucosal Immunol. 7, 763-774 (2013).
49. Jin, L., Batra, S. & Jeyaseelan, S. Deletion of Nlrp3 augments survival during polymicrobial sepsis by decreasing autophagy and enhancing phagocytosis. J. Immunol. 198, 1253-1262 (2016).
50. Jong, H. K. De et al. Limited role for ASC and NLRP3 during in vivo Salmonella typhimurium infection. BMC Immunol. 15, 30 (2014).
51. Man, S. M. et al. Inflammasome activation causes dual recruitment of NLRC4 and NLRP3 to the same macromolecular complex. Proc. Natl Acad. Sci. USA 111, 7403-7408 (2014).
52. Suzuki, N. et al. Mutual reinforcement of inflammation and carcinogenesis by the Helicobacter pylori CagA oncoprotein. Sci. Rep. 5, 10024 (2015).
53. Engler, D. B. et al. Helicobacter pylori-specific protection against inflammatory bowel disease requires the NLRP3 inflammasome and IL-18. Inflamm. Bowel Dis. 21, 854-861 (2015).
54. Ng, G. Z. et al. The MUC1 mucin protects against Helicobacter pylori pathogenesis in mice by regulation of the NLRP3 inflammasome. Gut 65, 1087-1099 (2016).
55. Mortimer, L., Moreau, F., Cornick, S. & Chadee, K. The NLRP3 inflammasome is a pathogen sensor for invasive Entamoeba histolytica via activation of a5b1 integrin at the macrophage-amebae intercellular junction. PLoS Pathog. 11, e1004887 (2015).
56. Mortimer, L., Moreau, F., Cornick, S. & Chadee, K. Gal-lectin-dependent contact activates the inflammasome by invasive Entamoeba histolytica. Mucosal Immunol. 7, 829-841 (2014).
57. Janowski, A. M., Kolb, R., Zhang, W. & Sutterwala, F. S. Beneficial and detrimental roles of NLRs in carcinogenesis. Front. Immunol 4, 370 (2013).
58. Castaño-Rodríguez, N., Kaakoush, N. O., Goh, K.-L., Fock, K. M. & Mitchell, H. M. The NOD-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer: a case-control study and gene expression analyses. PLoS ONE 9, e98899 (2014).
59. Ungerbäck, J. et al. Genetic variation and alterations of genes involved in NFkB/TNFAIP3-and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer. Carcinogenesis 33, 2126-2134 (2012).
60. Liu, R. et al. Expression profile of innate immune receptors, NLRs and AIM2, in human colorectal cancer: correlation with cancer stages and inflammasome components. Oncotarget 6, 33456-33469 (2015).
61. Zaki, M. H., Vogel, P., Body-Malapel, M., Lamkanfi, M. & Kanneganti, T.-D. IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J. Immunol. 185, 4912-4920 (2010).
62. Radtke, F. & Clevers, H. Self-renewal and cancer of the gut: two sides of a coin. Science 307, 1904-1909 (2005).
63. Du, Q. et al. Dietary cholesterol promotes AOM-induced colorectal cancer through activating theNLRP3 inflammasome. Biochem. Pharmacol. 105, 42-54 (2016).
64. Guo, W. et al. Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitisassociated cancer. Autophagy 10, 972-985 (2014).
65. Dupaul-Chicoine, J. et al. The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity 43, 751-763 (2015).
66. Bruchard, M. et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 19, 57-64 (2013).
67. Robblee, M. M. et al. Saturated fatty acids engage an IRE1a-dependent pathway to activate the NLRP3 inflammasome in myeloid cells. Cell Rep. 14, 2611-2623 (2016).
68. Ruiz, P. A. et al. Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome. Gut, gutjnl-2015-310297 (2016) (doi:10. 1136/gutjnl-2015-310297).
69. Progatzky, F. et al. Dietary cholesterol directly induces acute inflammasome-dependent intestinal inflammation. Nat. Commun. 5, 5864 (2014).
70. Bitzer, Z. T. et al. Soy protein concentrate mitigates markers of colonic inflammation and loss of gut barrier function in vitro and in vivo. J. Nutr. Biochem. 40, 201-208 (2017).
71. Youm, Y.-H. et al. The ketone metabolite b-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 21, 263-269 (2015).
72. Wolf, A. J. et al. Hexokinase is an innate immune receptor for the detection of bacterial peptidoglycan. Cell 166, 624-636 (2016).
73. Guo, C. et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity 45, 944 (2016).
74. Zhao, S. et al. Deoxycholic acid triggers NLRP3 inflammasome activation and aggravates dss-induced colitis in mice. Front. Immunol. 7, 536 (2016).
75. Macia, L. et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat. Commun. 6, 6734 (2015).
76. Mariathasan, S. et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430, 213-218 (2004).
77. Miao, E. A. et al. Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc. Natl Acad. Sci. USA 107, 3076-3080 (2010).
78. Miao, E. A. et al. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat. Immunol. 7, 569-575 (2006).
79. Sutterwala, F. S. & Flavell, R. A. NLRC4/IPAF: a CARD carrying member of the NLR family. Clin. Immunol. 130, 2-6 (2009).
80. Sadasivam, S. et al. Caspase-1 activator Ipaf is a p53-inducible gene involved in apoptosis. Oncogene 24, 627-636 (2005).
81. Thalappilly, S., Sadasivam, S., Radha, V. & Swarup, G. Involvement of caspase 1 and its activator Ipaf upstream of mitochondrial events in apoptosis. FEBS J. 273, 2766-2778 (2006).
82. Hu, B. et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc. Natl Acad. Sci. USA 107, 21635-21640 (2010).
83. Carvalho, F. A. et al. Cytosolic flagellin receptor NLRC4 protects mice against mucosal and systemic challenges. Mucosal Immunol. 5, 288-298 (2012).
84. Romberg, N. et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat. Genet. 46, 1135-1139 (2014).
85. Franchi, L. et al. NLRC4-driven production of IL-1b discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat. Immunol. 13, 449-456 (2012).
86. Sellin, M. E. et al. Epithelium-intrinsic NAIP/NLRC4 inflammasome drives infected enterocyte expulsion to restrict salmonella replication in the intestinal mucosa. Cell Host Microbe 16, 237-248 (2014).
87. Deng, W. et al. Dissecting virulence: systematic and functional analyses of a pathogenicity island. Proc. Natl Acad. Sci. USA 101, 3597-3602 (2004).
88. Liu, Z. et al. Role of inflammasomes in host defense against Citrobacter rodentium infection. J. Biol. Chem. 287, 16955-16964 (2012).
89. Nordlander, S., Pott, J. & Maloy, K. J. NLRC4 expression in intestinal epithelial cells mediates protection against an enteric pathogen. Mucosal Immunol. 7, 775-785 (2013).
90. Elinav, E. et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145, 745-757 (2011).
91. Normand, S. et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc. Natl Acad. Sci. USA 108, 9601-9606 (2011).
92. Gremel, G. et al. The human gastrointestinal tract-specific transcriptome and proteome as defined by RNA sequencing and antibody-based profiling. J. Gastroenterol. 50, 46-57 (2015).
93. Wlodarska, M. et al. NLRP6 inflammasome orchestrates the colonic hostmicrobial interface by regulating goblet cell mucus secretion. Cell 156, 1045-1059 (2014).
94. Birchenough, G. M. H., Nyström, E. E. L., Johansson, M. E. V. & Hansson, G. C. A sentinel goblet cell guards the colonic crypt by triggering Nlrp6-dependent Muc2 secretion. Science 352, 1535-1542 (2016).
95. Kempster, S. L. et al. Developmental control of the Nlrp6 inflammasome and a substrate, IL-18, in mammalian intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G253-G263 (2011).
96. Wang, P. et al. Nlrp6 regulates intestinal antiviral innate immunity. Science 350, 826-830 (2015).
97. Levy, M. et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell 163, 1428-1443 (2015).
98. Chudnovskiy, A. et al. Host-protozoan interactions protect from mucosal infections through activation of the inflammasome. Cell 167, 444-456. e14 (2016).
99. Sun, Y. et al. Stress-induced corticotropin-releasing hormone-mediated NLRP6 inflammasome inhibition and transmissible enteritis in mice. Gastroenterology 144, 1478-1487. 1487-8 (2013).
100. Hooper, L. V., Stappenbeck, T. S., Hong, C. V. & Gordon, J. I. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat. Immunol. 4, 269-273 (2003).
101. Hu, B. et al. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. Proc. Natl Acad. Sci. USA 110, 9862-9867 (2013).
102. Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179-185 (2012).
103. Chen, G. Y., Liu, M., Wang, F., Bertin, J. & Núñez, G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J. Immunol. 186, 7187-7194 (2011).
104. Mehta, R. et al. Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects. BMC Gastroenterol. 14, 208 (2014).
105. Seregin, S. S. et al. NLRP6 function in inflammatory monocytes reduces susceptibility to chemically induced intestinal injury. Mucosal Immunol. 10, 434-445 (2016).
106. Anand, P. K. et al. NLRP6 negatively regulates innate immunity and host defence against bacterial pathogens. Nature 488, 389-393 (2012).
107. Nour, A. M. et al. Anthrax lethal toxin triggers the formation of a membrane-associated inflammasome complex in murine macrophages. Infect. Immun. 77, 1262-1271 (2009).
108. Faustin, B. et al. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol. Cell 25, 713-724 (2007).
109. Williams, T. M. et al. The NLRP1 inflammasome attenuates colitis and colitis-associated tumorigenesis. J. Immunol. 194, 3369-3380 (2015).
110. Bürckstümmer, T. et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat. Immunol. 10, 266-272 (2009).
111. Fernandes-Alnemri, T. et al. The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat. Immunol. 11, 385-393 (2010).
112. Hornung, V. et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458, 514-518 (2009).
113. Wilson, J. E. et al. Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt. Nat. Med. 21, 906-913 (2015).
114. Hu, S. et al. The DNA sensor AIM2 maintains intestinal homeostasis via regulation of epithelial antimicrobial host defense. Cell Rep. 13, 1922-1936 (2015).
115. Ratsimandresy, R. A., Indramohan, M., Dorfleutner, A. & Stehlik, C. The AIM2 inflammasome is a central regulator of intestinal homeostasis through the IL-18/IL-22/STAT3 pathway. Cell. Mol. Immunol. 14, 127-142 (2016).
116. Hu, B. et al. The DNA-sensing AIM2 inflammasome controls radiationinduced cell death and tissue injury. Science 354, 765-768 (2016).
117. Hu, G.-Q. et al. AIM2 contributes to the maintenance of intestinal integrity via Akt and protects against Salmonella mucosal infection. Mucosal Immunol. 9, 1330-1339 (2016).
118. Schulmann, K. et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology 128, 590-599 (2005).
119. Woerner, S. M. et al. The putative tumor suppressor AIM2 is frequently affected by different genetic alterations in microsatellite unstable colon cancers. Genes Chromosomes Cancer 46, 1080-1089 (2007).
120. Dihlmann, S. et al. Lack of Absent in Melanoma 2 (AIM2) expression in tumor cells is closely associated with poor survival in colorectal cancer patients. Int. J. Cancer 135, 2387-2396 (2014).
121. Man, S. M. et al. Critical role for the DNA sensor AIM2 in stem cell proliferation and cancer. Cell 162, 45-58 (2015).
122. Zhang, L. et al. Cryo-EM structure of the activated NAIP2-NLRC4 inflammasome reveals nucleated polymerization. Science 350, 404-409 (2015).
123. Hu, Z. et al. Structural and biochemical basis for induced self-propagation of NLRC4. Science 350, 399-404 (2015).
124. Vance, R. E. The NAIP/NLRC4 inflammasomes. Curr. Opin. Immunol. 32, 84-89 (2015).
125. Maier, J. K. X. et al. The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7. J. Neurosci. 22, 2035-2043 (2002).
126. Davoodi, J., Ghahremani, M.-H., Es-Haghi, A., Mohammad-Gholi, A. & Mackenzie, A. Neuronal apoptosis inhibitory protein, NAIP, is an inhibitor of procaspase-9. Int. J. Biochem. Cell Biol. 42, 958-964 (2010).
127. Allam, R. et al. Epithelial NAIPs protect against colonic tumorigenesis. J. Exp. Med. 212, 369-383 (2015).
128. Endo, T. et al. Expression of IAP family proteins in colon cancers from patients with different age groups. Cancer Immunol. Immunother. 53, 770-776 (2004).
129. Wang, L. et al. PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing. J. Biol. Chem. 277, 29874-29880 (2002).
130. Shi, F. et al. Inflammasome-independent role of NLRP12 in suppressing colonic inflammation regulated by Blimp-1. Oncotarget 7, 30575-30584 (2016).
131. Tuncer, S., Fiorillo, M. T. & Sorrentino, R. The multifaceted nature of NLRP12. J. Leukoc. Biol. 96, 991-1000 (2014).
132. Zaki, M. H. et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 20, 649-660 (2011).
133. Allen, I. C. et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-kB signaling. Immunity 36, 742-754 (2012).
134. Zaki, M. H., Man, S. M., Vogel, P., Lamkanfi, M. & Kanneganti, T.-D. Salmonella exploits NLRP12-dependent innate immune signaling to suppress host defenses during infection. Proc. Natl Acad. Sci. USA 111, 385-390 (2014).
135. Karki, R. et al. NLRC3 is an inhibitory sensor of PI3K-mTOR pathways in cancer. Nature 540, 583-587 (2016).
136. Vanaja, S. K., Rathinam, V. A. K. & Fitzgerald, K. A. Mechanisms of inflammasome activation: recent advances and novel insights. Trends Cell Biol. 25, 308-315 (2015).
137. Shi, J. et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514, 187-192 (2014).
138. Hagar, J. A., Powell, D. A., Aachoui, Y., Ernst, R. K. & Miao, E. A. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science 341, 1250-1253 (2013).
139. Kayagaki, N. et al. Non-canonical inflammasome activation targets caspase-11. Nature 479, 117-121 (2011).
140. Kayagaki, N. et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 341, 1246-1249 (2013).
141. Aachoui, Y. et al. Caspase-11 protects against bacteria that escape the vacuole. Science 339, 975-978 (2013).
142. Man, S. M. et al. IRGB10 liberates bacterial ligands for sensing by the AIM2 and Caspase-11-NLRP3 inflammasomes. Cell 167, 382-396. e17 (2016).
143. Meunier, E. et al. Caspase-11 activation requires lysis of pathogencontaining vacuoles by IFN-inducedGTPases. Nature 509, 366-370 (2014).
144. Kayagaki, N. et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526, 666-671 (2015).
145. Rühl, S. & Broz, P. Caspase-11 activates a canonical NLRP3 inflammasome by promoting K() efflux. Eur. J. Immunol. 45, 2927-2936 (2015).
146. Schmid-Burgk, J. L. et al. Caspase-4 mediates non-canonical activation of the NLRP3 inflammasome in human myeloid cells. Eur. J. Immunol. 45, 2911-2917 (2015).
147. Williams, T. M. et al. Caspase-11 attenuates gastrointestinal inflammation and experimental colitis pathogenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 308, G139-G150 (2015).
148. Oficjalska, K. et al. Protective role for caspase-11 during acute experimental murine colitis. J. Immunol. 194, 1252-1260 (2015).
149. Demon, D. et al. Caspase-11 is expressed in the colonic mucosa and protects against dextran sodium sulfate-induced colitis. Mucosal Immunol. 7, 1480-1491 (2014).
150. Case, C. L. et al. Caspase-11 stimulates rapid flagellin-independent pyroptosis in response to Legionella pneumophila. Proc. Natl Acad. Sci. USA 110, 1851-1856 (2013).
151. Broz, P. et al. Caspase-11 increases susceptibility to Salmonella infection in the absence of caspase-1. Nature 490, 288-291 (2012).
152. Gabrielli, E. et al. Induction of caspase-11 by aspartyl proteinases of Candida albicans and implication in promoting inflammatory response. Infect. Immun. 83, 1940-1948 (2015).
153. Kobayashi, T. et al. The Shigella OspC3 effector inhibits Caspase-4, antagonizes inflammatory cell death, and promotes epithelial infection. Cell Host Microbe 13, 570-583 (2013).
154. Coutermarsh-Ott, S. L. et al. Caspase-11 modulates inflammation and attenuates Toxoplasma gondii pathogenesis. Mediators Inflamm. 2016, 9848263 (2016).
155. Pallett, M. A. et al. Bacterial virulence factor inhibits caspase-4/11 activation in intestinal epithelial cells. Mucosal Immunol. 2016 (doi:10. 1038/mi. 2016. 77).
156. Knodler, L. A. et al. Noncanonical inflammasome activation of Caspase-4/ Caspase-11 mediates epithelial defenses against enteric bacterial pathogens. Cell Host Microbe 16, 249-256 (2014).
157. Lupfer, C. R. et al. Reactive oxygen species regulate caspase-11 expression and activation of the non-canonical NLRP3 inflammasome during enteric pathogen infection. PLoS Pathog. 10, e1004410 (2014).
158. Franchi, L., Muñoz-Planillo, R. & Núñez, G. Sensing and reacting to microbes through the inflammasomes. Nat. Immunol. 13, 325-332 (2012).
159. Lin, K.-M. et al. IRAK-1 bypasses priming and directly links TLRs to rapid NLRP3 inflammasome activation. Proc. Natl Acad. Sci. USA 111, 775-780 (2014).
160. Elinav, E., Henao-Mejia, J. & Flavell, R. A. Integrative inflammasome activity in the regulation of intestinal mucosal immune responses. Mucosal Immunol. 6, 4-13 (2013).
161. Chae, J. J. et al. Gain-of-function Pyrin mutations induce NLRP3 proteinindependent interleukin-1b activation and severe autoinflammation in mice. Immunity 34, 755-768 (2011).
162. Agostini, L. et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20, 319-325 (2004).
163. Canna, S. W. et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat. Genet. 46, 1140-1146 (2014).
164. Sheedy, F. J. et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat. Immunol. 14, 812-820 (2013).
165. Rainone, V. et al. Upregulation of inflammasomeactivity and increased gut permeability are associated with obesity in children and adolescents. Int. J. Obes. (Lond) 40, 1026-1033 (2016).
166. Schroder, K., Zhou, R. & Tschopp, J. TheNLRP3 inflammasome: a sensor for metabolic danger?. Science 327, 296-300 (2010).
167. Youm, Y.-H. et al. The Nlrp3 inflammasome promotes age-related thymic demise and immunosenescence. Cell Rep. 1, 56-68 (2012).
168. Youm, Y.-H. et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab. 18, 519-532 (2013).
169. Mezzaroma, E. et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc. Natl Acad. Sci. USA 108, 19725-19730 (2011).
170. Malik, A. F. et al. Inflammasome components Asc and caspase-1 mediate biomaterial-induced inflammation and foreign body response. Proc. Natl Acad. Sci. USA 108, 20095-20100 (2011).
171. Pizarro, T. T. et al. IL-18, a novel immunoregulatory cytokine, is upregulated in Crohn's disease: expression and localization in intestinal mucosal cells. J. Immunol. 162, 6829-6835 (1999).
172. Ligumsky, M., Simon, P. L., Karmeli, F. & Rachmilewitz, D. Role of interleukin 1 in inflammatory bowel disease-enhanced production during active disease. Gut 31, 686-689 (1990).
173. Mahida, Y. R., Wu, K. & Jewell, D. P. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut 30, 835-838 (1989).
174. Casini-Raggi, V. et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J. Immunol. 154, 2434-2440 (1995).
175. Kanai, T. et al. Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease. Gastroenterology 119, 1514-1523 (2000).
176. Cummings, J. R. F. et al. The genetics of NOD-like receptors in Crohn's disease. Tissue Antigens 76, 48-56 (2010).
177. Ludicibus, S. De. et al. Genetic predictors of glucocorticoid response in pediatric patients with inflammatory bowel diseases. J. Clin. Gastroenterol. 45, e1-e7 (2011).
178. Yamamoto-Furusho, J. K. et al. Interleukin 1 b (IL-1B) and IL-1 antagonist receptor (IL-1RN) gene polymorphisms are associated with the genetic susceptibility and steroid dependence in patients with ulcerative colitis. J. Clin. Gastroenterol. 45, 531-535 (2011).
179. Tountas, N. A. et al. Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology 117, 806-813 (1999).
180. Villani, A.-C. et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat. Genet. 41, 71-76 (2009).
181. Schoultz, I. et al. Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn's disease in Swedish men. Am. J. Gastroenterol. 104, 1180-1188 (2009).
182. Roberts, R. L. et al. Evidence of interaction ofCARD8 rs2043211withNALP3 rs35829419 in Crohn's disease. Genes Immun. 11, 351-356 (2010).
183. Thompson, S. R. & Humphries, S. E. Interleukin-18 genetics and inflammatory disease susceptibility. Genes Immun. 8, 91-99 (2007).
184. Cho, J. H. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 8, 458-466 (2008).
185. van Heel, D. A. et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet (London, England) 365, 1794-1796 (2005).
186. Philpott, D. J., Sorbara, M. T., Robertson, S. J., Croitoru, K. & Girardin, S. E. NOD proteins: regulators of inflammation in health and disease. Nat. Rev. Immunol. 14, 9-23 (2014).
187. Grimes, C. L., Ariyananda, L. D. Z., Melnyk, J. E. & O'Shea, E. K. The innate immune protein nod2 binds directly to MDP, a bacterial cell wall fragment. J. Am. Chem. Soc. 134, 13535-13537 (2012).
188. Vaishnava, S., Behrendt, C. L., Ismail, A. S., Eckmann, L. & Hooper, L. V. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc. Natl Acad. Sci. USA 105, 20858-20863 (2008).
189. Ramanan, D., Tang, M. S., Bowcutt, R., Loke, P. & Cadwell, K. Bacterial sensor Nod2 prevents inflammation of the small intestine by restricting the expansion of the commensal Bacteroides vulgatus. Immunity 41, 311-324 (2014).
190. Petnicki-Ocwieja, T. et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc. Natl Acad. Sci. USA 106, 15813-15818 (2009).
191. Kobayashi, K. S. et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307, 731-734 (2005).
192. Rioux, J. D. et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet. 39, 596-604 (2007).
193. Hampe, J. et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 39, 207-211 (2007).
194. Lassen, K. G. et al. Atg16L1 T300Avariant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense. Proc. Natl Acad. Sci. USA 111, 7741-7746 (2014).
195. Saitoh, T. et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456, 264-268 (2008).
196. Simms, L. A. et al. Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. Gut 57, 903-910 (2008).
197. Wehkamp, J. et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 53, 1658-1664 (2004).
198. Huber, S. et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491, 259-263 (2012).
199. Alipour, M. et al. Mucosal barrier depletion and loss of bacterial diversity are primary abnormalities in paediatric ulcerative colitis. J. Crohn's Colitis 10, 462-471 (2016).
200. La Fuente, M. De. et al. Escherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate NLRP3 inflammasome. Int. J. Med. Microbiol. 304, 384-392 (2014).
201. Vanhove, W. et al. Strong upregulation of AIM2 and IFI16 inflammasomes in the mucosa of patients with active inflammatory bowel disease. Inflamm. Bowel Dis. 21, 2673-2682 (2015).
202. Carter, J. D., Valeriano, J. & Vasey, F. B. Crohn disease worsened by anakinra administration. J. Clin. Rheumatol. 9, 276-277 (2003).
203. Canna, S. W. et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J. Allergy Clin. Immunol., pii: S0091-6749(16)31352-5 (2016) (doi:10. 1016/ j. jaci. 2016. 10. 022).
204. Moon, J.-S. et al. NOX4-dependent fatty acid oxidation promotes NLRP3 inflammasome activation in macrophages. Nat. Med. 22, 1002-1012 (2016).
205. Duong, B. H. et al. A20 restricts ubiquitination of pro-interleukin-1b protein complexes and suppresses NLRP3 inflammasome activity. Immunity 42, 55-67 (2015).
206. Wei, W. et al. Rhapontin ameliorates colonic epithelial dysfunction in experimental colitis through SIRT1 signaling. Int. Immunopharmacol. 42, 185-194 (2017).
207. Coll, R. C. et al. A small-molecule inhibitor of the NLRP3 inflammasomefor the treatment of inflammatory diseases. Nat. Med. 21, 248-255 (2015).
208. Liu, W. et al. A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem. Pharmacol. 85, 1504-1512 (2013).
209. Wang, Y. et al. 3-(2-Oxo-2-phenylethylidene)-2, 3, 6, 7-tetrahydro-1Hpyrazino[ 2, 1-a]isoquinolin-4(11bH)-one (compound 1), a novel potent Nrf2/ARE inducer, protects against DSS-induced colitis via inhibiting NLRP3 inflammasome. Biochem. Pharmacol. 101, 71-86 (2016).
210. Guo, W. et al. Asiatic acid ameliorates dextran sulfate sodium-induced murine experimental colitis via suppressing mitochondria-mediated NLRP3 inflammasome activation. Int. Immunopharmacol. 24, 232-238 (2015).
211. Ke, P. et al. Activation of cannabinoid receptor 2 ameliorates DSS-induced colitis through inhibiting nlrp3 inflammasome in macrophages. PLoS ONE 11, e0155076 (2016).
212. Shaker, M. E., Ashamallah, S. A. & Houssen, M. E. Celastrol ameliorates murine colitis via modulating oxidative stress, inflammatory cytokines and intestinal homeostasis. Chem. Biol. Interact. 210, 26-33 (2014).
213. Otani, K. et al. Colchicine prevents NSAID-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Sci. Rep. 6, 32587 (2016).
214. Ferenczi, S., Szegi, K., Winkler, Z., Barna, T. & Kovács, K. J. Oligomannan prebiotic attenuates immunological, clinical and behavioral symptoms in mouse model of inflammatory bowel disease. Sci. Rep. 6, 34132 (2016).
215. Yan, Y. et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 38, 1154-1163 (2013).
216. He, X. et al. Alpinetin attenuates inflammatory responses by suppressing TLR4 and NLRP3 signaling pathways in DSS-induced acute colitis. Sci. Rep. 6, 28370 (2016).
217. Márquez-Flores, Y. K., Villegas, I., Cárdeno, A., Rosillo, M. Á. & Alarcón-de-la-Lastra, C. Apigenin supplementation protects the development of dextran sulfate sodium-induced murine experimental colitis by inhibiting canonical and non-canonical inflammasome signaling pathways. J. Nutr. Biochem. 30, 143-152 (2016).
218. Guo, W. et al. Fumigaclavine C ameliorates dextran sulfate sodiuminduced murine experimental colitis via NLRP3 inflammasome inhibition. J. Pharmacol. Sci. 129, 101-106 (2015).
219. Gregory, S. M. et al. Discovery of a viral NLR homolog that inhibits the inflammasome. Science 331, 330-334 (2011).
220. Li, Y. et al. A functional genomics approach to understand variation in cytokine production in humans. Cell 167, 1099-1110. e14 (2016).
221. Lee, M. N. et al. Common genetic variants modulate pathogen-sensing responses in human dendritic cells. Science 343, 1246980-1246980 (2014).
222. Kumar, V., Wijmenga, C. & Xavier, R. J. Genetics of immune-mediated disorders: from genome-wide association to molecular mechanism. Curr. Opin. Immunol. 31, 51-57 (2014).
223. Li, Y. et al. Inter-individual variability and genetic influences on cytokine responses to bacteria and fungi. Nat. Med. 22, 952-960 (2016).
224. Netea, M. G., Wijmenga, C. & O'Neill, L. A. J. Genetic variation in Toll-like receptors and disease susceptibility. Nat. Immunol. 13, 535-542 (2012).
225. Aguirre-Gamboa, R. et al. Differential effects of environmental and genetic factors on T and B cell immune traits. Cell Rep. 17, 2474-2487 (2016).
226. Ahern, P. P., Faith, J. J. & Gordon, J. I. Mining the human gutmicrobiota for effector strains that shape the immune system. Immunity 40, 815-823 (2014).
227. Zeevi, D. et al. Personalized nutrition by prediction of glycemic responses. Cell 163, 1079-1094 (2015).
228. Horst, R. T. et al. Host and environmental factors influencing individual human cytokine responses. Cell 167, 1111-1124. e13 (2016).